No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The highest dose level evaluated has been an intravenous loading dose of 32 mg/m2 followed by subcutaneous doses of 16 mg/m2 administered twice weekly. One rheumatoid arthritis patient mistakenly self-administered 62 mg Etanercept subcutaneously twice weekly for 3 weeks without experiencing undesirable effects. There is no known antidote to Etanercept.
Sign Out
